Two global, phase 3 trials of chronic cough show a global population with burdensome cough of long duration and substantial impairment to quality of life

Wednesday, November 2nd, 2022

This pooled analysis by Dicpinigaitis PV et al. examined the medical histories and clinical characteristics of 2044 adult patients with refractory or unexplained chronic cough enrolled in the Phase 3 COUGH-1 and COUGH-2 trials. This analysis of participants diagnosed with refractory chronic cough or unexplained chronic cough reflects a global population with severe and long-lasting cough who share characteristics with individuals in previous studies.

Two global, phase 3 trials of chronic cough show a global population with burdensome cough of long duration and substantial impairment to quality of life

The data highlighted “The existing burden of cough that is unresponsive to treatment of presumed associated conditions and reinforces the need for an effective treatment of chronic cough.”

In both studies, objective 24-hour cough frequency was calculated from recordings captured using the Vitalograph VitaloJAK device.